Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen Ruth M. Minimal residual disease (MRD) is a powerful determinant of overall outcome in multiple myeloma (MM) . Previous studies have demonstrated that the presence of MRD at the traditional day 100 assessment point following autologous stem cell transplant (ASCT) independently predicts for both progression free (PFS) and overall survival (OS). This effect on outcome is demonstrable in patients achieving a complete response (CR) and in those with both high-risk and standard-risk cytogenetics [1] [2] [3] [4] . As a consequence MRD assessment is currently being considered as a surrogate end-point for survival in academic clinical trials and for regulatory drug approval 5, 6 . Surrogate endpoints are clearly desirable in MM given the increasing complexity of treatment schedules and continually improving complete response rates and survival such that trials of up-front therapy require 5-10 years of follow up in order to demonstrate survival differences. Acceptance of MRD as an appropriate end-point would also ideally require the demonstration that this effect was independent of the treatment received. We have therefore MRC Myeloma IX was a multi-center, randomized phase III trial with protocol and clinical results previously reported 7, 8 . All patients provided written informed consent. This analysis involves 397 patients randomly assigned to CTD (cyclophosphamide, thalidomide, and dexamethasone; n=189) or CVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone; n=208) for four to six cycles, then high-dose melphalan (HDM, 200 mg/m2) and ASCT.
Bone marrow (BM) aspirates for MRD assessment were obtained at the end of induction (n=252) and at day 100 post ASCT (n=397). Patients were then randomly assigned to maintenance thalidomide (50 to 100 mg daily) or no further therapy. Flow cytometry for MRD detection was performed as reported previously. Briefly, assessing 500,000 cells incubated with six-colour antibody combinations including CD138/CD38/CD45/CD19 with CD56/CD27 in all cases and CD81/CD117 in some cases as required 3 . Statistical analyses were landmarked from date of MRD assessment with a median follow up of comparisons and survival (OS and PFS) was analyzed using Kaplan-Meier and the log-rank tests with a 5% significance level.
We have previously reported that the CTD regimen showed superior categorical response rates to CVAD. Figure 1A ) while the median OS was 80.6 months versus not reached (p=0.81, Figure 1B) . Similarly in MRD-positive patients outcome was identical with each induction regimen with median PFS of 14.9 months with CTD versus 15.9 months for CVAD (p=0.96, Figure 1A) and median OS 58.7 v 61.9 months (p=0.91, Figure 1B ). This pattern was also demonstrable when the PFS analysis was restricted to patients achieving a conventional immunofixation-negative complete response ( Figure 1C ).
We and others have previously demonstrated that the outcome of patients is also impacted by MRD at the end of induction as well as following ASCT such that the outcome is best in those MRD-negative at both time points and worst in those with detectable disease at both time points 1, 3 . We have also assessed this according to induction regimen and show no significant differences. In those patients who were MRD-negative at both time points the median PFS was 44.2 months for those receiving CTD and 40. The impact of MRD on outcome did not differ according to induction therapy received. For MRD-negative patients the median PFS for CTD was 28.9 months versus 28.7 months for CVAD (p=0.54, A) while the median OS was 80.6 months and not reached respectively (p=0.81, B). Similarly for MRDpositive patients median PFS for CTD was 14.9 months versus 15.9 months for CVAD (p=0.96, A) and median OS 58.7 months and 61.9 months respectively (p=0.91, B). A similar pattern is also seen when PFS analysis is restricted to CR patients (C). The outcome of MRD-positive patients with MRD levels of 0.01% -<0.1% (A), 0.1% -<1% (B) and greater than 1% (C) did not differ with induction regimen (p=0.84, 0.9 and 0.49 respectively).
